MX2021014271A - Sales farmaceuticamente aceptables de [2-(3-fluoro-5-metanosulfoni lfenoxi)etil](propil)amina y usos de las mismas. - Google Patents

Sales farmaceuticamente aceptables de [2-(3-fluoro-5-metanosulfoni lfenoxi)etil](propil)amina y usos de las mismas.

Info

Publication number
MX2021014271A
MX2021014271A MX2021014271A MX2021014271A MX2021014271A MX 2021014271 A MX2021014271 A MX 2021014271A MX 2021014271 A MX2021014271 A MX 2021014271A MX 2021014271 A MX2021014271 A MX 2021014271A MX 2021014271 A MX2021014271 A MX 2021014271A
Authority
MX
Mexico
Prior art keywords
nylphenoxy
sulfo
fluoro
methane
propyl
Prior art date
Application number
MX2021014271A
Other languages
English (en)
Inventor
Clas Sonesson
Ross Nicholas Waters
Inese Reine
Joakim Mihkel Tedroff
Original Assignee
Integrative Res Laboratories Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden Ab filed Critical Integrative Res Laboratories Sweden Ab
Publication of MX2021014271A publication Critical patent/MX2021014271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una sal de la Fórmula III, un método para fabricar la misma, así como usos de la misma (ver Fórmula) Fórmula III en donde X es H u OH, Y es H o un catión seleccionado del grupo que consiste en Li, Na y K, es un enlace sencillo o un doble enlace, y n es 0.5 o 1.
MX2021014271A 2019-05-24 2020-05-20 Sales farmaceuticamente aceptables de [2-(3-fluoro-5-metanosulfoni lfenoxi)etil](propil)amina y usos de las mismas. MX2021014271A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19176514 2019-05-24
EP20166361 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (1)

Publication Number Publication Date
MX2021014271A true MX2021014271A (es) 2022-01-06

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014271A MX2021014271A (es) 2019-05-24 2020-05-20 Sales farmaceuticamente aceptables de [2-(3-fluoro-5-metanosulfoni lfenoxi)etil](propil)amina y usos de las mismas.

Country Status (20)

Country Link
US (1) US20240343687A2 (es)
EP (2) EP4292653A3 (es)
JP (1) JP2022533433A (es)
KR (1) KR20220011638A (es)
CN (1) CN113853369A (es)
AU (1) AU2020286003A1 (es)
BR (1) BR112021023563A2 (es)
CA (1) CA3140805A1 (es)
CL (1) CL2021003115A1 (es)
CO (1) CO2021016556A2 (es)
DK (1) DK3976581T3 (es)
ES (1) ES2970361T3 (es)
FI (1) FI3976581T3 (es)
IL (1) IL288271B1 (es)
JO (1) JOP20210312A1 (es)
MX (1) MX2021014271A (es)
PL (1) PL3976581T3 (es)
PT (1) PT3976581T (es)
SG (1) SG11202112165QA (es)
WO (1) WO2020239568A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022101227A1 (en) * 2020-11-10 2022-05-19 Integrative Research Laboratories Sweden Ab [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias
WO2024042540A1 (en) * 2022-08-24 2024-02-29 Alkem Laboratories Limited Mesdopetam compositions
WO2024062344A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
US20100069346A1 (en) 2005-06-23 2010-03-18 Sara Holmqvist New Azetidine Derivatives as Neurokinin Receptor Antagonists for the Treatment of Gastrointestinal Diseases
CA2687721A1 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
JP5876140B2 (ja) 2011-04-19 2016-03-02 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー 皮質のドーパミン作動性及びｎｍｄａ受容体介在のグルタミン酸作動性神経伝達の新規なモジュレータ
MX2020001311A (es) * 2017-08-07 2020-03-20 Suven Life Sciences Ltd Compuestos de fluoropiperidina como antagonistas del receptor 5-hidroxitriptamina 6 puro.

Also Published As

Publication number Publication date
CN113853369A (zh) 2021-12-28
KR20220011638A (ko) 2022-01-28
JOP20210312A1 (ar) 2023-01-30
SG11202112165QA (en) 2021-12-30
IL288271B1 (en) 2024-10-01
JP2022533433A (ja) 2022-07-22
PT3976581T (pt) 2024-02-08
AU2020286003A1 (en) 2021-12-02
EP3976581A1 (en) 2022-04-06
FI3976581T3 (fi) 2024-01-31
BR112021023563A2 (pt) 2022-01-04
US20220267262A1 (en) 2022-08-25
DK3976581T3 (da) 2024-01-22
ES2970361T3 (es) 2024-05-28
US20240343687A2 (en) 2024-10-17
EP4292653A2 (en) 2023-12-20
CL2021003115A1 (es) 2022-09-30
WO2020239568A1 (en) 2020-12-03
PL3976581T3 (pl) 2024-07-01
CO2021016556A2 (es) 2022-01-17
EP3976581B1 (en) 2023-11-22
IL288271A (en) 2022-01-01
CA3140805A1 (en) 2020-12-03
EP4292653A3 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
MX2021014271A (es) Sales farmaceuticamente aceptables de [2-(3-fluoro-5-metanosulfoni lfenoxi)etil](propil)amina y usos de las mismas.
MX2022007969A (es) Inhibidores de egfr.
MX2017003518A (es) Estimuladores de guanilato ciclasa soluble (sgc).
GEP20125505B (en) Fungicidal azocylic amides
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
WO2006113509A3 (en) Quinobenzoxazine analogs and methods of using thereof
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
TW200637539A (en) CTGF inhibitors
AU2018274378A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
WO2019168688A3 (en) Quinolone analogs and their salts, compositions, and method for their use
WO2009047499A3 (en) Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
MX2023009037A (es) Compuesto de pirimidopirano.
WO2018232005A3 (en) Antimicrobial compounds and nanostructures
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
MY147951A (en) Crystalline potassium salt of lipoxin a? analogs
MA39715A (fr) Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
WO2012176218A8 (en) Process for preparing rosuvastatin calcium through novel amine salt
CR20240173A (es) Compuestos de cd73
SG11201907945YA (en) Azetidine derivative
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2022013528A (es) Procesos para la preparacion de un inhibidor de cinasa.
WO2021224902A3 (en) An improved process for the preparation of an aqueous ophthalmic solution of difluprednate
UA96149C2 (en) Method for producing 4-oxoquinoline compound